Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes

Lignende værker

• Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria
  af: Nakamura, Akinobu, et al.
  Udgivet: (2020)
• Protective effect of sodium–glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes
  af: Miyoshi, Hideaki, et al.
  Udgivet: (2019)
• Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
  af: Cho, Kyu Yong, et al.
  Udgivet: (2020)
• MON-492 A Case of Gitelman’s Syndrome with Hyperphosphatemia That Responded Effectively to Single Oral Administration of Magnesium Oxide
  af: Miya, Aika, et al.
  Udgivet: (2019)
• Gitelman's syndrome with hyperphosphatemia, effectively responding to single oral magnesium oxide administration: A case report
  af: Miya, Aika, et al.
  Udgivet: (2019)